Company Overview and News

25
TPG Specialty Lending's NAV Sustainability And Investment Rating Analysis (Post Q1 2018 Earnings)

2018-06-14 seekingalpha
Following continued requests from readers, this article first performs a FMV investing rating analysis on TSLX’s portfolio companies over the prior four quarters.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX JIVE NEWTL PBB

3
NEWT / Newtek Business Services Corp. PRELIMINARY PROXY STATEMENT

2018-06-13 sec.gov
tv495923-pre14a - none - 2.2715716s
NEWT

23
Main Street Capital's NAV, Dividend, And Valuation Compared To 14 BDC Peers (Post Q1 2018 Earnings) - Part 2

2018-06-12 seekingalpha
This article compares MAIN’s recent dividend per share rates, yield percentages, and several other dividend sustainability metrics to fourteen other BDC peers.
ACSF AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC MSCA TSLX NEWT SLRA MCC ARCC GBDC FSIC MAIN TCPC AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

25
TPG Specialty Lending's Dividend Sustainability Analysis (Includes Q3-Q4 2018 Dividend Projection)

2018-06-07 seekingalpha
Following multiple requests by readers, this article analyzes TSLX’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP SLRC RXNRP REXXQ MSCA TSLX NEWT SLRA MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX REXX NEWTL PBB

37
Newtek Business Services shares down 3.1% in Tuesday premarket trading

2018-06-05 marketwatch
Main Street Capital's NAV, Valuation, And Dividend Compared To 13 BDC Peers (Post Q1 2018 Earnings) - Part 1
AKTX MAIN CLTX FSCT HURC KBALA NEWTZ KBAL MSCA.CL MSCA CACC NEWT NEWTL

6
Newtek Small Business Finance, LLC Receives Reduction in Interest Rate for $100.0 Million Capital One Revolving Credit Facility

2018-06-04 globenewswire
LAKE SUCCESS, N.Y., June 04, 2018 (GLOBE NEWSWIRE) -- Newtek Business Services Corp. (“Newtek” or the “Company”) (NASDAQ:NEWT), an internally managed business development company ("BDC"), today announced that Newtek Small Business Finance, LLC, (“NSBF”), its SBA 7(a) lender subsidiary, received a 50 basis point reduction in the interest rate for its existing $100.0 million revolving credit facility through Capital One, National Association (“Capital One”), used to fund the unguaranteed and guaranteed portions of SBA 7(a) loans NSBF originates.
TSCC NEWT NEWTL NEWTZ

23
Gladstone  Investment's Dividend Sustainability Analysis (Includes July-December 2018 Dividend Projection)

2018-06-01 seekingalpha
Following multiple requests, this article analyzes GAIN’s dividend sustainability by performing three tests based on historical and projected future quarterly results.
AIY AINV GAIN MCQ GAINM MCV OSLE GADDP MSCA TSLX NEWT MCC ARCC FSIC MAIN AIB PSEC NEWTZ OCSI ARU OCSL MSCA.CL MCX NEWTL PBB

2
NEWT / Newtek Business Services Corp. null

2018-05-31 sec.gov
Eversheds Sutherland (US) LLP 700 Sixth Street, NW, Suite 700 Washington, DC 20001-3980
NEWT

2
NEWT / Newtek Business Services Corp. AUTO-GENERATED PAPER DOCUMENT

2018-05-23 sec.gov
This document was generated as part of a paper submission. Please reference the Document Control Number 18003794 for access to the original document.
NEWT

3
NEWT / Newtek Business Services Corp. FORM N-2

2018-05-16 sec.gov
tv493320-n2 - none - 173.6648716s TABLE OF CONTENTS
NEWT

2
NEWT / Newtek Business Services Corp. 497

2018-05-15 sec.gov
Document Filed Pursuant to Rule 497 Securities Act File No. 333-212436 NEWTEK BUSINESS SERVICES CORP.
NEWT

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Silicon Investor Message Boards

This table lists all message boards related to NEWT / Newtek Business Services Corp. on message board site Silicon Investor.

Did Newt Blow it for the GOP?
CUSIP: 652526203